Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on May 1, 2018. The report discloses a material event regarding the pricing of an underwritten public offering of the Company's common stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on the announcement of a capital raising event rather than periodic financial performance data.
Material Changes
The primary material change reported is the pricing of an underwritten public offering of common stock. The specific terms, share count, and proceeds from this offering are detailed in the press release furnished as Exhibit 99.1, which is not included in the provided text.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or a discussion of risks and contingencies beyond the standard disclosure that the press release information is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the specific offering price, number of shares sold, and total gross proceeds by reviewing Exhibit 99.1 (Press Release dated May 1, 2018).
- Confirm the identity of the underwriters and any over-allotment options associated with the offering.
- Review the Company's most recent 10-K or 10-Q filings for baseline financial data, as this 8-K does not contain historical financial metrics.